Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Are The Future Growth Projections For The Pulmonary Arterial Hypertension Market Size?
The market size for pulmonary arterial hypertension has witnessed considerable growth lately. Projections indicate that it will escalate from $8.47 billion in 2024 to $9.15 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. The significant surge in the past phase can be credited to a rise in knowledge and identification of pulmonary arterial hypertension (PAH), an upswing in healthcare spending, an increase in the elderly population, broadening of treatment methods for pulmonary arterial hypertension, and enhancements in research and development activities in the area of pulmonary hypertension.
Expectations are high for substantial expansion in the pulmonary arterial hypertension market in the coming years. It is projected to rise to “$12.69 billion in 2029 with an 8.5% compound annual growth rate (CAGR). The surge anticipated within the forecast period can be linked to the embrace of innovative treatments for pulmonary arterial hypertension, amplified emphasis on prompt detection and diagnosis, the expanding pipeline of PAH drugs and therapies, the integration of precision medicine in PAH treatment, and the growth of healthcare infrastructure in emerging markets. Important trends during the forecast period comprise advancements in medical imaging and diagnostic technologies, collaborations and partnerships aimed at drug creation, patient-focused strategies in managing pulmonary arterial hypertension, and increased utilization of combination therapy.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp
Which Industry Forces Are Driving The Pulmonary Arterial Hypertension Market Forward?
The rising occurrence of pulmonary arterial hypertension (PAH) disease is fuelling the expansion of the pulmonary arterial hypertension market. With more people suffering from PAH diseases and subsequently requiring hospitalization for treatment, there’s an anticipated surge in the need for appropriate medications during the predicted time frame. The National Organization for Rare Disorders, Inc. has published a study that suggests new occurrences of PAH are anticipated to affect between one and two persons per million annually in the USA, representing 500–1000 new cases each year. A comparable incidence rate is projected for Europe.
What Are The Primary Segmentation Parameters In The Pulmonary Arterial Hypertension Market?
The pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat
Which Emerging Trends Are Reshaping The Pulmonary Arterial Hypertension Market Landscape?
In the pulmonary arterial hypertension market, top-tier companies are developing state-of-the-art products like Winrevair, aiming to enhance treatment options and results for patients afflicted with this critical condition. For example, in March 2024, Winrevair was introduced by Merck & Co. Inc., a multinational pharmaceutical corporation based in the US, specifically for treating adults diagnosed with pulmonary arterial hypertension. Winrevair has the distinction of being the first therapy approved by the US-based federal agency, the Food and Drug Administration (FDA), that targets activin signaling for pulmonary arterial hypertension (PAH). This groundbreaking treatment method functions by re-establishing equilibrium between pro- and anti-proliferative signals, thus managing the vascular cell proliferation related to PAH. Consequently, it heralds a new therapeutic category for this condition.
Who Are The Dominant Players In The Pulmonary Arterial Hypertension Market Today?
Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Pulmonary Arterial Hypertension Market?
North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
